½ÃÀ庸°í¼­
»óǰÄÚµå
1279711

¼¼°èÀÇ ´ç´¢º´¼º Á·ºÎ±Ë¾ç ½ÃÀå(2023-2030³â)

Global Diabetic Foot Ulcer Market - 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ÃÀå °³¿ä

¼¼°è ´ç´¢º´¼º Á·ºÎ±Ë¾ç ½ÃÀåÀº 2022³â 58¾ï 1,270¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2030³â¿¡´Â 93¾ï 60¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ç´¢º´¼º Á·ºÎ±Ë¾ç ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È 6.2%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ç´¢º´¼º Á·ºÎ±Ë¾çÀº ´ç´¢º´ÀÌ Á¦´ë·Î °ü¸®µÇÁö ¾Ê´Â »ç¶÷µé¿¡°Ô¼­ °¡Àå ÈçÇÏ°Ô ³ªÅ¸³ª´Â °á°ú Áß ÇϳªÀÔ´Ï´Ù. Ç÷´ç °ü¸® ¹ÌÈí, ±âÀú ½Å°æ Àå¾Ö, ¸»ÃÊÇ÷°ü Áúȯ ¶Ç´Â ºÒÃæºÐÇÑ ¹ß °ü¸® µîÀÌ ´ç´¢º´¼º Á·ºÎ±Ë¾çÀÇ ÈçÇÑ ¿øÀÎÀÔ´Ï´Ù.

´ç´¢º´¼º Á·ºÎ±Ë¾çÀº ½ÅüÀÇ »óó Ä¡À¯ ´É·ÂÀÌ ÇöÀúÇÏ°Ô °¨¼ÒÇϱ⠶§¹®¿¡ ´ç´¢º´ ȯÀÚ°¡ Á÷¸éÇÏ´Â °¡Àå ½É°¢ÇÑ »óȲ Áß ÇϳªÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î ȯÀÚÀÇ ¹ß¿¡ »óó°¡ »ý±â°í, ±× »óó´Â °ð ½â¾î ƯÁ¤ ºÎÀ§¿¡¼­ °¨¿°¼º ¹ÚÅ׸®¾Æ¸¦ ¹ß»ý½Ãŵ´Ï´Ù.

½ÃÀå ¿ªÇÐ

´ç´¢º´¼º Á·ºÎ±Ë¾çÀÇ À¯º´·ü Áõ°¡

´ç´¢º´ÀÌ °¡Á®¿À´Â °¡Àå ½É°¢ÇÏ°í ½É°¢ÇÑ °á°ú Áß Çϳª´Â ´ç´¢º´¼º Á·ºÎ±Ë¾çÀÔ´Ï´Ù. ´ç´¢º´ÀÇ À¯º´·üÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ ¹®Á¦µµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ç´¢º´¼º Á·ºÎ±Ë¾ç ¹ß»ýÀ» Áõ°¡½ÃŰ´Â ¿äÀÎÀº ¿¬·ÉÀÇ Áõ°¡, ÁÂ½Ä »ýȰ½À°ü, ´ç´¢º´ À¯º´±â°£ÀÇ ¿¬Àå µî ´Ù¾çÇÑ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù.

Ä¡·á¹ý ±â¼ú ¹ßÀü

ÃֽŠÈÞ´ëÆùÀº ½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â µðÁöÅÐ Ä«¸Þ¶ó¿¡ ¹ö±Ý°¡´Â °íÇØ»óµµ DFU À̹ÌÁö¸¦ ÃÔ¿µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç ¸¹Àº ȯÀÚµéÀÌ ÈÞ´ëÆù »çÁøÀ¸·Î DFU¸¦ ÀÚ°¡ °ü¸®Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠȯÀÚµéÀº DFU Ä¡·áÀÇ ÈÄ¼Ó Á¶Ä¡¸¦ À§ÇØ ¹ß Ŭ¸®´Ð¿¡ »çÁøÀ» °¡Á®¿Í Á¤±âÀûÀ¸·Î »óóÀÇ °æ°ú¸¦ °üÂûÇϴ ȯÀÚµµ ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ °æ¿ì, ȯÀÚ´Â ¿Â¶óÀÎ ¶Ç´Â À̸ÞÀÏ Ã·ºÎ ÆÄÀÏ·Î ¹ß °ü¸® Á¦°øÀÚ¿¡°Ô À̹ÌÁö¸¦ º¸³»±âµµ ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»ó Á¤º¸¸¦ ±â¹ÐÀ» À§¹ÝÇÏÁö ¾Ê°í ¾ÈÀüÇÏ°Ô °øÀ¯ÇÏ´Â °ÍÀº ÇöÀç·Î¼­´Â ¾î·ÆÁö¸¸, DFUÀÇ ÁøÇà »óȲÀ» ½º½º·Î ¸ð´ÏÅ͸µÇϱâ À§ÇØ ÈÞ´ëÆù »çÁøÀ» ³Î¸® »ç¿ëÇÏ´Â °ÍÀº ¹Ì·¡ÀÇ ¹ß °ü¸®¸¦ º¯È­½Ãų ¼ö ÀÖ½À´Ï´Ù.

´ç´¢º´¼º Á·ºÎ±Ë¾ç Ä¡·á¿¡´Â °íºñ¿ëÀÌ ¼Ò¿äµÈ´Ù

´ç´¢º´¼º Á·ºÎ±Ë¾çÀº »óó µå·¹½Ì, ¾à¹°, ÀæÀº ¸ð´ÏÅ͸µ µî Àå±âÀûÀ̰í ÁýÁßÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå±â°£ÀÇ Ä¡·á´Â Ä¡·á ºñ¿ëÀÇ Áõ°¡·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ´ç´¢º´¼º Á·ºÎ±Ë¾ç Ä¡·á¿¡´Â Á·ºÎ Àü¹®ÀÇ, »óóġ·á Àü¹®ÀÇ, ³»ºÐºñ Àü¹®ÀÇ, Ç÷°ü¿Ü°ú Àü¹®ÀÇ µî ¿©·¯ ÀÇ·á Àü¹®°¡°¡ Âü¿©ÇÏ´Â ´ÙÇÐÁ¦Àû Á¢±ÙÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. ´Ù¾çÇÑ ÀÇ·áÁø °£ÀÇ Ä¡·á Á¶Á¤Àº ÃÑ ºñ¿ëÀ» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù.

COVID-19 ¿µÇ⠺м®

COVID-19ÀÇ ´ëÀ¯ÇàÀº Àü ¼¼°èÀûÀ¸·Î DFU Ä¡·á¿¡ Å« ÁöÀåÀ» ÃÊ·¡Çß½À´Ï´Ù. ±Ë¾ç Æò°¡ÀÇ Áö¿¬Àº DFUÀÇ Ä¡À¯¿¡ ¾Ç¿µÇâÀ» ¹ÌÄ¡°í Àý´ÜÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

ÆÒµ¥¹Í ±â°£ µ¿¾È ÀüÈ­ ¹× È­»ó Áø·á¼Ò´Â COVID-19 ºÀ¼â ±â°£ µ¿¾È ȯÀÚµéÀÌ ÀÇ·á Ŭ¸®´ÐÀ» ¹æ¹®ÇÏÁö ¸øÇÏ´Â °Í°ú °ü·ÃµÈ ¸î °¡Áö ¿ì·Á¸¦ ÇØ°áÇϱâ À§ÇØ ÀÇ»çµéÀ» µµ¿Ô½À´Ï´Ù. °úÇа迡¼­´Â °¡»ó Ŭ¸®´ÐÀ» ÅëÇØ ȯÀÚ Ä¡·á¸¦ °³¼±ÇÏ´Â ÀΰøÁö´É(AI) ¾Ë°í¸®ÁòÀ» ±¸ÃàÇÏ·Á´Â ½Ãµµ°¡ Àü¿°º´¿¡ ´ëÀÀÇϱâ À§ÇØ ÁöÁö¹Þ¾Ò½À´Ï´Ù.

·¯½Ã¾Æ¿Í ¿ìÅ©¶óÀ̳ªÀÇ °¥µî ºÐ¼®

¿ìÅ©¶óÀ̳ª¿¡¼­´Â ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ºÎÁ·ÇÏ¿© ¼öõ ¸íÀÇ »ç¶÷µéÀÌ ´ç´¢º´¼º Á·ºÎ±Ë¾çÀ» ¾Î°í ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ ÇϹݽŠÀý´Ü À§Çè¿¡ ³ëÃâµÇ¾î ÀÖ½À´Ï´Ù. ¸¸¼º ±Ë¾ç ¹× Àý´Ü°ú °ü·ÃµÈ Àå¾Ö¸¦ ÇØ°áÇÏÁö ¾ÊÀ¸¸é ¿ìÅ©¶óÀ̳ªÀÇ °³Àΰú ´ëÁßÀÇ °Ç°­ÀÌ ¼Õ»óµÉ ¼ö ÀÖ½À´Ï´Ù.

ÀÏÂ÷ Áø·á¿Í ¿ø°Ý Áø·áÀÇ °­È­, °³Àκ° ÀÚ°¡ °ü¸® ±³À°, ´ç´¢º´¼º Á·ºÎ Ä¡·á¸¦ À§ÇÑ ÀûÀýÇÑ ¹°Ç° Á¦°øÀº Àý´Ü, Àå¾Ö, »ç¸Á·üÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¿ìÅ©¶óÀ̳ª¿Í ´Ù¸¥ ºÐÀï Áö¿ª¿¡¼­ ÃæºÐÇÑ ´ç´¢º´ ¹ß °ü¸®¸¦ Á¦°øÇÏ´Â °ÍÀº Áö¿ª ÁÖ¹ÎÀÇ °Ç°­°ú ÇÇÇØ ±¹°¡°¡ À§±â ÀÌÈÄ È¸º¹ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

  • Á¶»ç ¹æ¹ý
  • Á¶»ç ¸ñÀû ¹× Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

  • Á¦Ç° À¯Çüº° ³»¿ª
  • ±Ë¾ç Á¾·ùº° ³»¿ª
  • ÃÖÁ¾»ç¿ëÀÚº° ³»¿ª
  • Áö¿ªº° ³»¿ª

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ´ç´¢º´¼º Á·ºÎ±Ë¾ç À¯º´·ü Áõ°¡
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
      • ´ç´¢º´¼º Á·ºÎ±Ë¾ç ³ôÀº Ä¡·áºñ
    • ±âȸ
      • Ä¡·á ¿É¼ÇÀÇ ±â¼úÀû Áøº¸
    • ¿µÇ⠺м®

Á¦5Àå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±ÔÁ¦ ºÐ¼®

Á¦6Àå COVID-19 ºÐ¼®

  • COVID-19 ºÐ¼®
    • COVID-19ÀÇ Àü ½Ã³ª¸®¿À
    • COVID-19 ±â°£ Áß ½Ã³ª¸®¿À
    • COVID-19 ÀÌÈÄ ½Ã³ª¸®¿À ¶Ç´Â ÇâÈÄ ½Ã³ª¸®¿À
  • COVID-19 Áß¿¡¼­ÀÇ °¡°Ý¡¤¿ªÇÐ
  • ¼ö±Þ ½ºÆåÆ®·³
  • ÆÒµ¥¹Í µ¿¾È ½ÃÀå°ú °ü·ÃµÈ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
  • Á¦Á¶¾÷üÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
  • ¿ä¾à

Á¦7Àå Á¦Ç° À¯Çüº°

  • â»ó Ä¡·á¿ë µå·¹½Ì
  • ¹ÙÀÌ¿À·ÎÁ÷½º
  • ±âŸ

Á¦8Àå ±Ë¾ç À¯Çüº°

  • ½Å°æº´Áõ¼º ±Ë¾ç
  • ½Å°æ¡¤ÇãÇ÷¼º ±Ë¾ç

Á¦9Àå ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Áø·á¼Ò
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ÀçÅÃÀÇ·á

Á¦10Àå Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ³²¹Ì
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï »óȲ

  • °æÀï ½Ã³ª¸®¿À
  • ½ÃÀå »óȲ/Á¡À¯À² ºÐ¼®
  • M&A(ÀμöÇÕº´) ºÐ¼®

Á¦12Àå ±â¾÷ °³¿ä

  • ConvaTec Inc
  • Acelity LP Inc
  • 3M Healthcare
  • Organogenesis Inc
  • Coloplast Corp
  • Smith & Nephew Plc
  • B Braun Melsungen AG
  • Medline Industries Inc
  • Medtronic
  • Molnlycke Healthcare AB

Á¦13Àå ºÎ·Ï

ksm 23.06.05

Market Overview

The global diabetic foot ulcers market reached US$ 5,812.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 9,300.6 million by 2030. The diabetic foot ulcers market is expected to exhibit a CAGR of 6.2% during the forecast period (2023-2030). Diabetic foot ulcers are one of the most prevalent consequences in persons with poorly managed diabetes mellitus. Inadequate glycemic management, underlying neuropathy, peripheral vascular disease, or inadequate foot care are common causes of diabetic foot ulcers.

Diabetic foot ulcers are one of the most serious consequences that diabetics confront since the body's wound healing capacity has been greatly diminished. It is the creation of a wound, generally in the patient's foot, which decomposes quickly and leads to the generation of infectious germs in that specific location.

Market Dynamics

Increase in the Prevalence Of Diabetic Foot Ulcers

One of the most serious and severe consequences of diabetes is diabetic foot ulcer. As the prevalence of disease increases, so do the number of problems. Various variables, including rising age, sedentary lifestyle, and longer duration of diabetes mellitus, have all contributed to an increase in the occurrence of diabetic foot ulcers.

Technological Advancements In Treatment Options

Newer mobile phones can take high-resolution DFU images that are equivalent to those taken by commercial digital cameras. Many patients currently self-monitor their DFUs using cell phone photographs. Some patients painstakingly bring these photographs to foot clinics throughout their follow-up appointments for DFU therapy to serially track their wound development.

Patients occasionally send images to footcare providers online or as email attachments. Although the safety difficulties associated with the secure sharing of such clinical information without breaching confidentiality are currently hard, the widespread use of mobile phone photography for self-monitoring of DFU development may transform future foot care.

High Cost For Treatment Of Diabetic Foot Ulcers

Diabetic foot ulcers may need long-term and intense treatment, such as wound dressings, medicines, and frequent monitoring. This prolonged duration may lead to increased treatment expenses. Diabetic foot ulcer treatment often entails a multidisciplinary approach including several healthcare experts such as podiatrists, wound care specialists, endocrinologists, and vascular surgeons. Coordination of care among various providers may increase total costs.

COVID-19 Impact Analysis

The COVID-19 pandemic caused significant hurdles in DFU treatment over the world. Delays in ulcer evaluations may have a negative impact on DFU healing, potentially leading to amputations.

During the pandemic, telephone and video clinics assisted physicians in addressing some of the concerns connected to patients' incapacity to attend medical clinics during the COVID-19 lock-down period. Attempts by the scientific community to build artificial intelligence (AI) algorithms to improve patient care through virtual clinics gained traction in response to the epidemic.

Russia- Ukraine Conflcit Analysis

Due to the country's inadequate access to healthcare services, thousands of individuals in Ukraine suffer from diabetic foot ulcers and are consequently at significant risk of lower limb amputation. Individual and public health in Ukraine may suffer if the handicap associated with chronic ulcers and amputations is not addressed.

Strengthening primary and remote care, teaching individuals on self-care, and providing appropriate supplies for diabetic foot treatment have the potential to significantly reduce amputations, disability, and mortality. Adequate diabetic foot care in Ukraine and other conflict-torn regions is critical for the health of the local population and the ability of affected countries to recover after the crisis.

Segment Analysis

The Neuropathic Segment Is Expected To Have The Market Share Of Around 46.5% Over The Forecast Period.

Neuropathic ulcers are the most prevalent form of ulcer encountered in patients. As a result, this sector is dominated in the market in this category. This kind of disease is the most difficult to manage since it causes significant pain and agony to the individual; as a result, the usage of medications increases, helping to raise the revenue return for the diabetic foot ulcer treatment market.

Neuropathic ulcers arise when a patient with impaired peripheral nervous system neurological function has pressure sites that induce ulceration via the epidermal and dermal tissue layers. This is a frequent ailment that affects the foot and occasionally other sections of the body.

Geographical Analysis

North America is Expected to be the Dominating Region During The Forecast Period.

The North America region holds the largest share of the global diabetic foot ulcers market accounting for around 37.7% in the forecast period. This is owing the large number of diabetic patients and adequate healthcare facilities in this region. Also, North America also has lengthy R&D facilities and approval periods. The country also contains cutting-edge biologics and wound care equipments for the treatment of these ulcers.

Competitive Landscape

The major global players include: ConvaTec Inc, Acelity LP Inc, 3M Healthcare, Organogenesis Inc, Coloplast Corp Smith & Nephew Plc, B Braun Melsungen AG Medline Industries Inc, Medtronic, Molnlycke Healthcare AB and others.

  • Why Purchase the Report?
  • To visualize the global diabetic foot ulcers market segmentation based on the product type, ulcer type, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global diabetic foot ulcers market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global diabetic foot ulcers market report would provide approximately 92 tables, 108 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Ulcer Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased prevalence of diabetic foot ulcers
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of treatment for Diabetic foot ulcers
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements in treatment options
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Wound Care Dressing
  • 7.2. Biologics
  • 7.3. Others

8. By Ulcer Type

  • 8.1. Neuropathic Ulcers
  • 8.2. Neuro-Ischemic Ulcers

9. By End User

  • 9.1. Hospitals
  • 9.2. Clinics
  • 9.3. Ambulatory Surgical Center
  • 9.4. Homecare Setting

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ulcer Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. ConvaTec Inc
  • 12.2. Acelity LP Inc
  • 12.3. 3M Healthcare
  • 12.4. Organogenesis Inc
  • 12.5. Coloplast Corp
  • 12.6. Smith & Nephew Plc
  • 12.7. B Braun Melsungen AG
  • 12.8. Medline Industries Inc
  • 12.9. Medtronic
  • 12.10. Molnlycke Healthcare AB

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦